	US 11,708,351 B2
	Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
Jason Allan Wiles, Madison, CT (US); Avinash S. Phadke, Branford, CT (US); Milind Deshpande, Madison, CT (US); Atul Agarwal, Hamden, CT (US); Dawei Chen, Guilford, CT (US); Venkat Rao Gadhachanda, Hamden, CT (US); Akihiro Hashimoto, Branford, CT (US); Godwin Pais, Hamden, CT (US); Qiuping Wang, Bethany, CT (US); Xiangzhu Wang, Branford, CT (US); Joel Charles Barrish, Richboro, CT (US); William Greenlee, Teaneck, NJ (US); and Kyle J. Eastman, New Haven, CT (US)
Assigned to Achillion Pharmaceuticals, Inc., Boston, MA (US)
Filed by Achillion Pharmaceuticals, Inc., Boston, MA (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,670.
Application 17/366,670 is a continuation of application No. 16/555,914, filed on Aug. 29, 2019, granted, now 11,084,800.
Application 16/555,914 is a continuation of application No. PCT/US2018/020528, filed on Mar. 1, 2018.
Claims priority of provisional application 62/466,301, filed on Mar. 2, 2017.
Claims priority of provisional application 62/465,782, filed on Mar. 1, 2017.
Prior Publication US 2022/0396563 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 471/04 (2006.01); C07D 471/08 (2006.01); C07D 491/107 (2006.01); C07D 498/10 (2006.01); C07F 5/02 (2006.01)

CPC C07D 401/14 (2013.01) [C07D 403/14 (2013.01); C07D 409/14 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 491/107 (2013.01); C07D 498/10 (2013.01); C07F 5/027 (2013.01)]

17 Claims

1. A method of treating a disorder mediated by complement cascade Factor D, the method comprising administering to a subject ion need thereof an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.